Associated Papers
PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL.
Lahera A et al.
Npj Precision Oncology, 2024
39033228 (PubMed )
Supplement: 41698_2024_638_MOESM1_ESM.pdf
RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia.
Kubota H et al.
Blood Advances, 2024
38127276 (PubMed )
Supplement: BLOODA_ADV-2023-011583-mmc1.xlsx › Sup.11
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
Ascierto PA et al.
Nature Communications, 2024
38167503 (PubMed )
Supplement: 41467_2023_44475_MOESM1_ESM.pdf
Targeted panel sequencing in the routine diagnosis of mature T- and NK-cell lymphomas: report of 128 cases from two German reference centers.
Böck J et al.
Frontiers in Oncology, 2023
37664054 (PubMed )
Supplement: Table_1.xlsx › Table_S2
Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia.
Cheng WY et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
36442087 (PubMed )
Supplement: pnas.2211429119.sd02.xlsx › snv_indel
Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators.
Fornerod M et al.
Blood Cancer Discovery, 2021
34778799 (PubMed )
Supplement: bloodcandisc-2-586-s001.xlsx › Supplementary_Table_12
Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection.
Eletto D et al.
Nature Communications, 2016
Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.
Hornakova T et al.
Haematologica, 2011
Select a paper to view details